Adhera Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ATRX Over the counter 8731 https://adherathera.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adhera Therapeutics Inc

Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ - May 19th, 2022 1:15 pm
Adhera Therapeutics Names Preeminent Diabetes Pioneer Dr. Jean Buteau to Scientific Advisory Board - Mar 21st, 2022 1:37 pm
Adhera Therapeutics Announces Uplisting to OTCQB Venture Marketplace - Jan 20th, 2022 1:45 pm
Adhera Therapeutics Receives Notice of Allowance for New Canadian Patent Covering MLR-1019 for Dyskinesia and Related Disorders - Nov 22nd, 2021 3:00 pm
Adhera Therapeutics Announces Appointment of Dr. Zahed Subhan to Board of Directors - Nov 8th, 2021 2:15 pm
Adhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary Inflammation to Portfolio of Target Indications - Oct 20th, 2021 1:35 pm
Manufacturing Commences on Adhera’s MLR-1019 for Phase 2a Clinical Trial Treating Parkinson’s Disease - Oct 15th, 2021 2:21 pm
Adhera Receives European Patent Covering MLR-1019 and Derivatives for Treating Dyskinesias - Oct 4th, 2021 1:15 pm
Adhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson’s Disease and Type 1 Diabetes Drugs - Sep 13th, 2021 2:28 pm
Adhera Therapeutics Appoints Dr. Andrew Reaume to Board of Directors - Sep 9th, 2021 1:05 pm
Adhera Therapeutics Signs Exclusive License Agreement with Melior Pharmaceuticals I for New Type 1 Diabetes Drug Candidate - Aug 24th, 2021 1:20 pm
Adhera Signs Definitive License Agreement with Melior Pharmaceuticals II for New Parkinson’s Disease Drug Candidate - Jul 29th, 2021 1:00 pm
Adhera Therapeutics Signs Letter of Intent with Melior Pharmaceuticals II to Acquire a New Class of Drug for Parkinson’s Disease - Jun 7th, 2021 12:45 pm